Prescription Weight Loss Drugs: Science and Boundaries

Prescription weight loss drugs treat obesity and its complications. They are not cosmetic tools. Approval generally requires a BMI of 28 or above, or 24 or above with at least one related condition such as hypertension, high blood lipids, type 2 diabetes, or obstructive sleep apnea. The injections cut appetite and food intake. They only work alongside diet and exercise, and the weight comes back when you stop.

What prescription weight loss drugs actually treat

Here is the misunderstanding that causes most of the trouble. People think this category of medicine exists for anyone who wants to look thinner. It does not.

So: you have a BMI of 23, you would like to lose four kilograms, can you get a shot? No. That answer sits at the top of the article on purpose, because everything else depends on it.

Obesity is a chronic disease with diagnostic thresholds and a recurring course. It brings cardiovascular disease, type 2 diabetes, fatty liver, sleep apnea, and joint damage along with it. Prescription weight loss drugs exist because that disease needs options sitting between lifestyle change and surgery. Obesity medication fills that gap.

The distinction is practical, not moral. Suppress appetite in a person with a normal BMI and you get metabolic cost with nothing on the other side of the ledger. Appetite is a regulated signal. Turning it down in someone who does not need it turned down means losing lean mass, nutrients, and hormonal stability for a look.

The weight loss drug BMI requirement: who qualifies for prescription weight loss drugs

Qualification is arithmetic. Body mass index, or BMI, is weight in kilograms, divided by height in meters, divided by height in meters again. Somebody 1.70 m tall hits a BMI of 28 at about 81 kg, and a BMI of 24 at about 69 kg.

In China, under indications set by the National Medical Products Administration (NMPA), the weight loss indication runs on two branches and the prescribing gate runs on three.

BMI range	Approval status for weight loss medication	Notes
28 and above	Qualifies	Confirmed obesity
24 to 27.9 with at least one metabolic complication	Qualifies	The complication has to be documented: hypertension, dyslipidemia, high blood glucose, obstructive sleep apnea, fatty liver, cardiovascular disease
24 to 27.9 with no complications	Does not qualify	Overweight on its own is not an indication
Below 24	Does not qualify	Off-label use in healthy people is drug misuse

The three-part gate adds one more path. A prescriber can move when the patient has a BMI of 28 or above with confirmed simple obesity, or a BMI of 24 or above with a metabolic complication, or three documented months of dietary control and exercise with no real weight reduction. Those are the doors. There is no fourth one.

Other countries set the entry point lower on the scale but keep the same shape. In the United States, the same injectables are usually labelled for a BMI of 30 or above, or 27 or above with at least one weight-related condition. Different number, identical logic. This is a disease treatment with an entry criterion, and you either meet it or you do not.

The two drug families at a glance

Five products, two mechanisms. One family changes how appetite is signaled in the brain and gut. The other blocks fat absorption in the intestine.

Nothing on the market dissolves fat. No injection melts adipose tissue. If a product claims otherwise, it is not describing a real drug.

Drug	Class	Route and schedule	Signature feature
Semaglutide	GLP-1 single agonist	Subcutaneous injection, once weekly	Earliest launch, deepest clinical dataset, only weight loss drug approved to cut cardiovascular risk in obesity with existing heart disease
Tirzepatide	GIP and GLP-1 dual agonist	Subcutaneous injection, once weekly, abdomen, thigh, or upper arm	Largest average weight reduction, more gastrointestinal effects
Mazdutide	GLP-1 and GCG dual agonist	Subcutaneous injection, once weekly	Built around Asian metabolic profiles, and the GCG arm accelerates fat breakdown and energy expenditure
Benaglutide	GLP-1 agonist	Subcutaneous injection three times daily, five minutes before meals	Gentlest average effect, most demanding schedule
Orlistat	Gastrointestinal lipase inhibitor	Oral, 120 mg three times daily with a meal or up to an hour after	Sold without a prescription in many markets, blocks absorption of roughly 30 percent of dietary fat

How GLP-1 weight loss injections actually work

Think of a satiety switch in the brain. The GLP-1 family flips it from outside the body.

Eat a meal and your intestine releases GLP-1. That hormone tells the brain the meal was enough and tells the stomach to slow down. In obesity and type 2 diabetes the loop goes quiet. You can eat past the point of need because the stop signal never arrives clearly, and the stomach clears food fast enough that hunger returns early.

GLP-1 receptor agonists put that signal back. Four things follow.

Appetite drops as the brain reads satiety. Gastric emptying slows, so a smaller portion feels filling for longer. Insulin secretion rises in a glucose-dependent way, which smooths blood sugar after eating. Glucagon release falls, which trims the liver’s contribution to fat storage.

Now notice what the drug is not doing. It does not destroy fat cells. It does not bend energy balance. It lowers how much you eat and how urgently you want to eat, which finally makes a calorie deficit survive contact with a normal day. That is the whole mechanism. It also explains why the drugs work, and why they stop working the moment they stop.

Semaglutide: the single-target benchmark

Semaglutide, sold as Ozempic for type 2 diabetes and as Wegovy for weight management, is the yardstick. One receptor, one weekly injection, and the first of its class to reach the weight loss market.

Its clinical record is the widest here, which counts for a lot when a drug is taken for years rather than weeks. Safety data have had time to accumulate. Semaglutide weight loss figures are the best documented in the class. Sustained treatment over 44 weeks produced average weight loss of 13.5 percent, with waist circumference down 11.4 cm.

It also holds a card no competitor has matched. Semaglutide is the only weight loss medication approved to reduce the risk of major cardiovascular events in people who have obesity plus established cardiovascular disease. If your real risk is a heart attack rather than a number on a scale, that approval reframes the decision.

Who does it fit? Moderate to severe obesity with a genuine need for substantial reduction, and especially obesity with diabetes or a fragile cardiovascular history.

Tirzepatide: the dual-target drug with the strongest average result

Tirzepatide, sold as Mounjaro for type 2 diabetes and as Zepbound for weight management, presses two receptors instead of one: glucose-dependent insulinotropic polypeptide (GIP) and GLP-1. Two signals. Harder brake.

Dosing starts at 2.5 mg per week, moves to 5 mg after four weeks, and then climbs in 2.5 mg steps as tolerated, up to a ceiling of 15 mg per week. You can inject into the abdomen, the thigh, or the upper arm.

Three indications are approved: blood glucose control in adults with type 2 diabetes, long-term weight management at a BMI of 28 or above or a BMI of 24 or above with at least one weight-related complication, and moderate to severe obstructive sleep apnea in adults with obesity.

Tirzepatide weight loss results top the group. Over 52 weeks, average weight loss landed between 14.4 and 19.9 percent, with waist reduction of 11.9 to 16.4 cm.

You pay for that in tolerability. Two receptors means stronger gastrointestinal effects, and nausea, bloating, and vomiting run higher than with semaglutide. Semaglutide presses one brake pedal. Tirzepatide presses two. The car slows faster and the passengers feel worse.

Mazdutide: the GLP-1 and GCG dual agonist

Mazdutide is a dual agonist designed around Asian metabolic profiles, pairing GLP-1 with glucagon receptor (GCG) activity. Those two arms pull opposite ways on blood sugar, and that is the interesting part. Appetite suppression comes from the GLP-1 side. The GCG side raises energy expenditure and speeds up fat breakdown.

That second arm earns mazdutide its niche. Because GCG activity goes after fat metabolism directly, it holds up well when obesity comes with significant fatty liver disease.

It reached the Chinese market in 2025 at a much lower price than the first generation of injectables. At 2025 launch pricing, a two-vial pack listed at about 319 yuan, against the four-figure cost of early single injections. Prices move and vary by region, so check current figures.

Over 48 weeks, average weight loss was 12.0 to 14.8 percent, with waist down 9.4 to 10.9 cm. It suits Asian patients with metabolic obesity, and it is worth a conversation when fatty liver is already on the problem list.

Benaglutide: the mild option with the heaviest schedule

Benaglutide goes the other way. Instead of chasing the biggest effect, it lowers the floor on tolerability.

The schedule is the price. Three subcutaneous injections a day, five minutes before each meal. That is a lot more work than one weekly shot, and it assumes you can structure your meals predictably.

Over 16 weeks of standard treatment, average weight loss was 6.0 percent, waist down 4.91 cm.

Modest is the point. Benaglutide fits people who need a small reduction, who react to medication easily, or who simply cannot sit through a stronger appetite suppressant.

Orlistat: the oral drug that blocks fat absorption

Orlistat, sold under brand names including Xenical and Alli, is the oral option, and it is the closest thing this category has to prescription weight loss pills. It held China’s weight loss indication longer than anything else here. Its mechanism has nothing to do with appetite.

Picture your small intestine as a highway and dietary fat as the traffic. Normally, enzymes called lipases unload the fat and move it into the bloodstream. Orlistat blocks those unloading stations. Fat drives straight through and leaves in stool.

Roughly 30 percent of ingested fat never gets absorbed. That is the whole basis of the oil-blocking effect people talk about.

Take orlistat 120 mg three times daily, with a meal or up to an hour after. The indication covers a BMI of 24 or above in obesity or overweight, alongside a mildly reduced-calorie diet. Many markets sell it without a prescription. Talk to a doctor before the first dose anyway.

The side effects fall directly out of the mechanism, and they are not subtle. Oily spotting on underwear. More gas. Sudden urgency. Fatty or oily stool. Steatorrhea. More frequent bowel movements. Fecal incontinence. Abdominal pain and bloating. Eat a high-fat meal while on it and every item on that list gets worse, which is how some patients end up in pads.

Rare but serious liver events have been reported, including acute hepatocellular necrosis and acute liver failure. Loss of appetite, itching, jaundice, dark urine, pale stool, or right upper abdominal pain means stop the drug and get care now.

Do not use it if you are under 18, pregnant, or breastfeeding. Same for chronic malabsorption syndromes, cholestasis, organic causes of obesity such as hypothyroidism, organ transplant recipients, and anyone taking cyclosporine. A BMI below 24 also rules it out.

And one myth needs killing. Orlistat is not the one safe weight loss drug you can take freely. Regulators in the United States warned in 2010 about rare but severe liver injury with it. Available without a prescription does not mean harmless.

How the reported results compare

Drug	Treatment duration	Average weight reduction	Average waist reduction
Semaglutide	44 weeks	13.5 percent	11.4 cm
Tirzepatide	52 weeks	14.4 to 19.9 percent	11.9 to 16.4 cm
Mazdutide	48 weeks	12.0 to 14.8 percent	9.4 to 10.9 cm
Benaglutide	16 weeks	6.0 percent	4.91 cm
Orlistat	One year of label trials	Modest, a few kilograms beyond diet alone	Not reported as a percentage endpoint

Read the durations before you compare the percentages. Forty-four weeks and sixteen weeks describe two points on a curve, not two runners on the same track.

Weight loss drug contraindications: who must never use these drugs

Some contraindications are conditional. Others are absolute. For the GLP-1 injectables, this list is absolute.

A personal or family history of medullary thyroid carcinoma rules them out. So does multiple endocrine neoplasia syndrome type 2 (MEN2). So does a previous episode of acute pancreatitis, and so does severe gastrointestinal disease such as gastroparesis or active inflammatory bowel disease.

Pregnancy, breastfeeding, and active family planning all disqualify use. If you plan to conceive, stop at least two months beforehand. Nobody under 18 is included.

Uncontrolled severe psychiatric illness needs its own conversation. Trials of other long-term weight management products have reported suicidal behavior and ideation, so depression with suicidal thinking calls for monitoring, not a routine prescription.

What unsupervised use looks like

A widely reported case in China shows the failure mode end to end. A woman got tirzepatide without medical supervision, injected it herself, and kept pushing the dose up. Her weight fell from 80 kg to 45 kg in about six months. Then she was admitted with ketoacidosis, pale, severely weak, head aching, hurting in multiple parts of her body.

None of that was bad luck. Fast, unsupervised weight loss without nutritional support drives the body into fat-burning ketosis, and stacked with vomiting or plain undereating it can tip into ketoacidosis, which is an emergency. The dose escalation took out the one safeguard in the system.

Rebound weight gain after stopping weight loss drugs

Every injectable here is approved on the explicit condition that it is used alongside dietary control and increased physical activity. That wording is not legal boilerplate. It is a description of how the drug produces its effect.

Stop the drug and appetite walks back in. If your eating and activity never changed, the weight comes back with it, often right to where you started. Nothing has been reset. Nothing has been permanently altered. The drug held the deficit open while you built habits, and if you did not build them, the deficit closes.

Side effects that need attention

Gastrointestinal effects are close to universal: nausea, bloating, vomiting, diarrhea or stubborn constipation, and appetite so low that eating becomes a chore. Many people find these ease over time. Some never tolerate them, and their quality of life drops enough that stopping is the right call.

Two organ systems deserve specific vigilance. GLP-1 drugs can trigger cholecystitis and gallstones, and in serious cases acute pancreatitis, an emergency that shows up as severe abdominal pain. Rapid weight loss raises gallbladder risk on its own, so part of the danger is speed rather than the molecule.

Nutritional depletion and other knock-on effects

When appetite is suppressed by a drug, undereating becomes easy and invisible. Protein and micronutrient intake slide, and it shows up as hair loss, fatigue, anemia. Menstrual irregularity is common. Push far enough and the pattern tips into anorexic thinking and disordered eating, which is the opposite of success.

Orlistat has its own version of the same problem. It reduces absorption of vitamins A, D, E, and K and beta-carotene. Anyone taking it should supplement these fat-soluble vitamins, either two hours after the orlistat dose or at bedtime, so the drug is not sitting in the gut at the same time as the pill.

The part that surprises people: drugs buy time, they do not cure

Here is the counterintuitive finding of the whole category. The strongest drug is not the one that solves the problem.

Tirzepatide produces the biggest average reduction. It is also the drug most likely to be abandoned for tolerability, and the one most likely to be followed by rebound if the food environment around the patient never changed.

So the predictive variable is not the molecule. It is whether you change what you eat and how much you move while the drug is holding your appetite down. The medication opens the window. It does not use it.

Which brings the honest framing. Treating obesity with these drugs looks far more like treating hypertension than like taking a course of antibiotics. Blood pressure medication does not cure hypertension either. It controls it, and stop the control and the pressure climbs back. That is not a drug failing. That is what obesity treatment looks like when the condition is chronic.

Where these drugs sit in the weight management pyramid

Ranked by intensity, bottom to top.

The base is lifestyle: dietary control and regular physical activity. Everybody uses this layer. No exceptions, no opt-outs, no matter which drug is on the table.

Next is medical nutrition therapy combined with structured exercise intervention. This applies to everyone who is overweight or obese.

Then comes medication, indicated at a BMI of 28 or above, or 24 or above with a complication.

At the top sits metabolic and bariatric surgery, reserved for severe obesity.

Weight loss drugs live in the upper half of that pyramid and nowhere near the base. Pull the base out and the whole thing comes down, top layers included.

Practical guidance if you are considering these drugs

Get a diagnosis before you chase a prescription. Obesity is classified, not estimated. BMI plus screening for metabolic complications decides whether any of these products is even indicated.

Do not buy these drugs online, through personal shoppers, or on social commerce. Counterfeit and badly stored injectables are a real hazard, and self-injection removes the dose supervision that prevents the worst outcomes.

Work with a specialist medical weight management clinic. Proper intake means obesity classification, a health assessment, and risk screening before the first dose. Pancreatitis history, family thyroid cancer history, and pregnancy plans each change the decision.

If orlistat is your choice, talk to a physician first even without a prescription, and add supplementation with fat-soluble vitamins.

Plan the exit before you start. Ask what is going to change in your eating and activity while the appetite suppression is doing its work, because that answer decides where your weight lands after the last dose.

Report severe abdominal pain, persistent vomiting, or any sign of liver trouble immediately. Do not wait for the next appointment.

Limitations of this overview

The percentages above are treatment-arm averages from trials. Individual results spread widely, and landing below the average says nothing about whether the drug failed you.

Durations differ across products, so the comparison table is indicative rather than controlled. No head-to-head trial sits behind it.

Prices and approval details move fast. The figures here reflect the Chinese market at launch and should be checked against current information.

This article is general information, not medical advice. It cannot substitute for a clinician assessing your own BMI, your complications, and your contraindications.

Bottom line

These are serious prescription medicines for a diagnosed chronic disease. There is an entry threshold, and there is a list of people who must never take them. The mechanism is appetite suppression and reduced food intake, not fat dissolution. The average reductions are real and clinically meaningful. So are the side effects, and so is the rebound when you stop. The drug makes a calorie deficit survivable. Diet and exercise are what make it stick.

FAQ

What BMI do you need to qualify for prescription weight loss drugs?

Weight loss medication is generally approved at a BMI of 28 or above, or a BMI of 24 or above with at least one related condition such as hypertension, high blood lipids, high blood glucose, obstructive sleep apnea, fatty liver, or cardiovascular disease. A BMI below 24 does not qualify. Some countries set the entry threshold at 30, or 27 with a weight-related condition.

What is the difference between semaglutide and tirzepatide?

Semaglutide activates one receptor, the GLP-1 receptor. Tirzepatide activates two, GIP and GLP-1. In trials, tirzepatide produced larger average weight reduction, 14.4 to 19.9 percent over 52 weeks against 13.5 percent over 44 weeks for semaglutide. Tirzepatide also causes more gastrointestinal side effects. Semaglutide is the only one approved to reduce cardiovascular risk in obesity with heart disease.

How much weight do GLP-1 weight loss injections typically take off?

Reported averages are 13.5 percent over 44 weeks for semaglutide, 14.4 to 19.9 percent over 52 weeks for tirzepatide, 12.0 to 14.8 percent over 48 weeks for mazdutide, and 6.0 percent over 16 weeks for benaglutide. These are trial averages, so individual results vary. Weight reduction continues while treatment continues and usually reverses after treatment stops.

Is orlistat a safe weight loss pill?

Orlistat is not risk-free. It blocks absorption of roughly 30 percent of dietary fat, which causes oily spotting, urgency, fatty stool, and fecal incontinence, especially with high-fat meals. Rare but serious liver injury has been reported, and regulators warned about it in 2010. It also reduces absorption of vitamins A, D, E, and K, so supplementation is needed. It is not suitable for casual use.

Why do you gain weight back after stopping weight loss drugs?

These drugs work by suppressing appetite and slowing gastric emptying, not by permanently changing metabolism or the appetite signal. When treatment stops, hunger returns to its previous level. If eating and activity patterns have not changed, the calorie deficit closes and weight returns, often to the starting point. Ongoing diet and exercise are what determine the outcome after the last dose.

Who should never use GLP-1 weight loss injections?

Absolute contraindications include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, prior acute pancreatitis, severe gastrointestinal disease such as gastroparesis or active inflammatory bowel disease, pregnancy, breastfeeding, and active plans to conceive within two months. Anyone under 18 is excluded, and uncontrolled severe psychiatric illness requires monitoring.

Can you use weight loss injections without diet and exercise?

No. Every product in this class is approved on the condition that it is used alongside dietary control and increased physical activity. The drug lowers appetite so that a calorie deficit becomes achievable without constant hunger. It does not create the deficit by itself. Without dietary change, the weight lost on treatment returns once treatment stops.

What are the most common side effects of weight loss injections?

Nausea, bloating, vomiting, diarrhea or severe constipation, and markedly reduced appetite affect most patients, and they are more pronounced with dual agonist drugs such as tirzepatide. Symptoms often ease over weeks. Serious risks include cholecystitis, gallstones, and acute pancreatitis. Rapid weight loss also raises gallbladder risk independently of the drug itself.

How does mazdutide differ from other weight loss injections?

Mazdutide is a dual agonist that combines GLP-1 activity with glucagon receptor activity, and it was developed around Asian metabolic profiles. The glucagon arm increases energy expenditure and accelerates fat breakdown, which gives it an edge where obesity is accompanied by significant fatty liver disease. Average weight reduction was 12.0 to 14.8 percent over 48 weeks.

Can you buy weight loss injections online?

No. These are strictly controlled prescription medicines, and buying them online, through personal shoppers, or through social commerce is both illegal in most markets and unsafe. Counterfeit products and unreliable cold-chain handling are real risks. Dosing decisions require a physician, and unsupervised dose escalation has caused severe harm, including hospitalization for ketoacidosis.

Why do weight loss drugs cause gallbladder and pancreatitis problems?

Rapid fat mobilization during substantial weight loss increases cholesterol saturation of bile, which promotes gallstone formation and cholecystitis. That risk exists with any fast weight reduction, not only with drugs. GLP-1 drugs additionally slow gastric emptying, which is thought to contribute to pancreatitis risk. Severe abdominal pain during treatment is an emergency, not a side effect to wait out.

Do weight loss drugs cure obesity?

No. They control appetite while they are taken, and the effect reverses when they stop. Obesity behaves like a chronic condition in which treatment controls rather than cures, similar to blood pressure medication. Ongoing dietary control and physical activity are what hold the result after treatment ends. The drug opens a window for those changes. It does not make them.